Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GMAB)
NASDAQ:GMAB
Holding GMAB?
Track your performance easily
GMAB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$24.53 - $37.97
Previous Close$26.2
Volume531.09K
Average Volume (3M)573.46K
Market Cap
$17.22B
Enterprise Value$13.16B
Total Cash (Recent Filing)kr28.14B
Total Debt (Recent Filing)kr770.00M
Price to Earnings (P/E)21.3
Beta0.66
Next Earnings
Nov 06, 2024EPS Estimate
$0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.23
Shares Outstanding660,745,350
10 Day Avg. Volume403,601
30 Day Avg. Volume573,456
Standard Deviation0.10
R-Squared0.28
Alpha-0.00251
Financial Highlights & Ratios
Price to Book (P/B)0.55
Price to Sales (P/S)7.11
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$44.50Price Target Upside68.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Genmab News
PremiumCompany Announcements
Genmab Announces Strategic Financial UpdatesBulls Say, Bears Say
Bulls Say
Clinical Trial ResultsGenmab presented updated results from the dose-escalation and initial results from the dose-expansion portion of the Phase 1/2 trial, showing responses in ovarian cancer patients regardless of FRα expression levels.
Pipeline DevelopmentGenmab intends to initiate a pivotal Phase 3 trial for FRα+ PROC and other tumors, which could drive significant future upside.
Product ApprovalThe European Commission has approved Ordspono™ (odronextamab) to treat adult patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.
Bears Say
Clinical Trials60% of OC patients treated at the in dose expansion experienced a G3+ TEAE, with 20% of patients having a dose reduction due to a TEAE, and 10% of patients discontinuing treatment due to a TEAE.
Market SentimentGMAB has faced notable pressure YTD, with shares down >10% vs. an NBI up ~8% for the year.
PartnershipsBioNTech recently opted not to participate in the further development of the acasunlimab program under the parties’ existing collaboration agreement.
---
Ownership Overview
0.00%
Insiders
1.85% Mutual Funds
2.41% Other Institutional Investors
95.74% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GMAB FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest stock price was $24.53 and its highest was $37.97 in the past 12 months.
What is Genmab A/S’s market cap?
Currently, no data Available
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is Nov 06, 2024 which is in 47 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Aug 08, 2024. The company reported $0.317 earnings per share for the quarter, beating the consensus estimate of $0.311 by $0.006.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is $0.32.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 661,768,300 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of $0.317 in its last earnings report, beating expectations of $0.311. Following the earnings report the stock price went up 2.305%.
Which hedge fund is a major shareholder of Genmab A/S?
Among the largest hedge funds holding Genmab A/S’s share is Graham Capital Management, L.P.. It holds Genmab A/S’s shares valued at 595K.
---
Genmab Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$44.50 (68.05% Upside)
$44.50 (68.05% Upside)
Blogger Sentiment
Bullish
GMAB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 27.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 3.2%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.92%
12-Months-Change
Fundamentals
Return on Equity
18.45%
Trailing 12-Months
Asset Growth
18.45%
Trailing 12-Months
Company Description
Genmab A/S
Genmab A/S is an international biotech company. It is specialized in creating and developing differentiated antibody therapeutics for the treatment of cancer. The company currently markets DARZALEX monoclonal antibody for the treatment of patients with multiple myeloma and Arzerra monoclonal antibody for the treatment of chronic lymphocytic leukemia.
---
GMAB Company Deck
---
GMAB Earnings Call
Q2 2024
0:00 / 0:00
---
GMAB Stock 12 Month Forecast
Average Price Target
$44.50
▲(68.05% Upside)
Technical Analysis
Best Analysts Covering GMAB
1 Year
1 Year Success Rate
2/14 ratings generated profit
1 Year Average Return
-8.66%
assigned a buy rating 11 days ago
Copying Asthika Goonewardene's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -8.66% per trade.
---